Literature DB >> 30196344

Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry.

Ido Weinberg1, Jay Giri2, Raghu Kolluri3, Juan Ignacio Arcelus4, Conxita Falgá5, Silvia Soler6, Andrei Braester7, José Bascuñana8, Javier Gutiérrez-Guisado9,10, Manuel Monreal11,12.   

Abstract

Knee arthroscopy is the most common orthopedic procedure worldwide. While incidence of post-arthroscopy venous thromboembolic events (VTE) is low, treatment patterns and patient outcomes have not been described. Patients from the "Registro Informatizado Enfermedad TromboEmbolica" who had confirmed post-arthroscopy VTE were compared to patients with provoked, post bone-fracture, and to patients with unprovoked VTE. Baseline characteristics, presenting signs and symptoms, treatment and outcomes including recurrent VTE, bleeds or death were compared. A total of 101 patients with post-arthroscopy VTE and 19,218 patients with unprovoked VTE were identified. Post-arthroscopy patients were younger (49.5 vs. 66 years, P < 0.0001) and had less history of VTE [5.9% vs. 20%, OR 0.26 (0.11-0.59)]. Among patients with isolated DVT, there were fewer proximal DVT in the post-arthroscopy group [40% vs. 86%, OR 0.11 (0.06-0.19)]. Treatment duration was shorter in the post-arthroscopy group (174 ± 140 vs. 311 ± 340 days, P < 0.0001) and more often with DOAC [OR 3.67 (1.95-6.89)]. Recurrent VTE occurred in 6.18 (1.96-14.9) and 11.9 (11.0-12.8) per 100 patient years [HR 0.52 (0.16-1.26)] after treatment in the post-arthroscopy and unprovoked groups, respectively. Recurrent VTE occurred in 5.17 (1.31-14.1) per 100 patient years in a separate post bone-fracture group (n = 147), also not statistically different than the post-arthroscopy recurrence rate. After anticoagulation cessation, some patients post-knee arthroscopy develop VTE. While our small sample size precludes drawing firm conclusions, this signal should warrant further research into the optimal treatment duration for these patients, as some patients may be at increased risk for long-term recurrence.

Entities:  

Keywords:  Anticoagulation; Arthroscopy; Deep vein thrombosis; Knee arthroscopy; Pulmonary embolism; Venous thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 30196344     DOI: 10.1007/s11239-018-1736-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  28 in total

1.  Mortality of untreated deep vein thrombosis following knee arthroscopy.

Authors:  P Egermayer
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

2.  Incidence of symptomatic and asymptomatic venous thromboembolism after elective knee arthroscopic surgery: a retrospective study with routinely applied venography.

Authors:  Ye Sun; Dongyang Chen; Zhihong Xu; Dongquan Shi; Jin Dai; Jianghui Qin; Qing Jiang
Journal:  Arthroscopy       Date:  2014-04-24       Impact factor: 4.772

3.  Fatal pulmonary embolus after knee arthroscopy.

Authors:  R Rozencwaig; J S Shilt; J L Ochsner
Journal:  Arthroscopy       Date:  1996-04       Impact factor: 4.772

4.  The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy.

Authors:  Banne Nemeth; Raymond A van Adrichem; Suzanne C Cannegieter
Journal:  Thromb Haemost       Date:  2016-09-15       Impact factor: 5.249

5.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.

Authors:  J A Heit; D N Mohr; M D Silverstein; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  2000-03-27

6.  Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study.

Authors:  R A van Adrichem; R G H H Nelissen; I B Schipper; F R Rosendaal; S C Cannegieter
Journal:  J Thromb Haemost       Date:  2015-06-05       Impact factor: 5.824

7.  Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy.

Authors:  K T Delis; N Hunt; R K Strachan; A N Nicolaides
Journal:  Thromb Haemost       Date:  2001-09       Impact factor: 5.249

Review 8.  Thromboembolic complications after arthroscopy of the knee.

Authors:  K A Poulsen; L C Borris; M R Lassen
Journal:  Arthroscopy       Date:  1993       Impact factor: 4.772

9.  An unusual case of pulmonary embolism after arthroscopic meniscectomy.

Authors:  Jong Keun Seon; Eun Kyoo Song; Taek Rim Yoon; Sang Jin Park; Hyoung Yeon Seo
Journal:  Arch Orthop Trauma Surg       Date:  2006-03-07       Impact factor: 3.067

10.  Efficacy of Rivaroxaban for thromboprophylaxis after Knee Arthroscopy (ERIKA). A phase II, multicentre, double-blind, placebo-controlled randomised study.

Authors:  Giuseppe Camporese; Enrico Bernardi; Franco Noventa; Mario Bosco; Giuseppe Monteleone; Luca Santoro; Cristiano Bortoluzzi; Stefano Freguja; Michela Nardin; Matteo Marullo; Giacomo Zanon; Claudio Mazzola; Guido Damiani; Pietro Maniscalco; Davide Imberti; Corrado Lodigiani; Cecilia Becattini; Chiara Tonello; Giancarlo Agnelli
Journal:  Thromb Haemost       Date:  2016-04-14       Impact factor: 5.249

View more
  1 in total

1.  Prophylaxis for preventing venous thromboembolism in knee arthroscopy and soft tissue reconstruction: consensus statements from an international panel of experts.

Authors:  Raju Easwaran; Moin Khan; Parag Sancheti; Ashok Shyam; Mohit Bhandari; Anil S Ranawat; Savyasachi Thakkar; Shital Parikh; Volker Musahl; Siddharth Joglekar; Ajit J Deshmukh; Kevin Plancher; Nikhil Verma; David McAllister; Peter Verdonk; Sebastien Lustig; Amit Chandrateya; Robert Smigleiski; Gandhi Solayar; Bancha Chernchujit; Patrick Yung; Nicolaas Budhiparama; Yuichi Hoshino; Nathan White; David Parker; Mark Clatworthy; Charlie Brown; Mojieb Manzary; David Rajan; Abhay Narvekar; Sachin Tapasvi; Dinshaw Pardiwala; Ranjit Panigrahi; S Arumugam; Vikash Kapoor; Bharat Mody; Jitender Maheshwari; Vivek Dahiya; Clement Joseph; Mukesh Laddha; Ashok Rajgopal
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-04-18       Impact factor: 4.114

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.